AbbVie Inc. ABBV
Set alert
At close · Oct 30
After hours · Oct 30, 6:40 PM ET
- YTD
- +29.06%
- 1 year
- +29.22%
- Open
- 292.00
- Prev close
- 290.79
- Mkt cap
- 521.11B
- Vol
- 6.90M
- Avg vol
- 4.72M
- EPS
- 3.54
- P/E
- 83.30
- Div yield
- 2.38%
More statistics
- Low
- 291.01
- High
- 298.74
- Forward P/E
- 18.15
- Beta
- 0.23
- Short ratio
- 3.22
- Inst. own
- 77.38%
- Dividend
- 6.92
- Ex-div date
- Oct 14, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 268.63
- 200-d avg
- 236.73
- 1y target
- 283.19
MAX chart
Events in this range
- Feb 4, 2026Earnings: 2.71; estimate 2.65; surprise 2.26%
- Oct 30, 2026Earnings: 3.82; estimate 3.73; surprise 2.41%
Signals (57)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Apr 1, 2026 | 7 months ago |
| MACD: Buy Signal | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | May 1, 2025 | 1 year ago |
| MACD: Sell Signal | May 1, 2025 | 1 year ago |
| SMA: Bullish | Jan 1, 2025 | 1 year ago |
| SMA: Bearish | Dec 1, 2024 | 1 year ago |
| MACD: Buy Signal | Feb 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 1, 2023 | 3 years ago |
| MACD: Buy Signal | Nov 1, 2022 | 4 years ago |
| SMA: Bullish | Oct 1, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| RSI: Overbought | Jan 1, 2022 | 4 years ago |
| SMA: Bullish | Oct 1, 2021 | 5 years ago |
| SMA: Bearish | Sep 1, 2021 | 5 years ago |
| SMA: Bullish | Nov 1, 2020 | 6 years ago |
| SMA: Bearish | Sep 1, 2020 | 6 years ago |
| SMA: Bullish | May 1, 2020 | 6 years ago |
| MACD: Buy Signal | May 1, 2020 | 6 years ago |
| SMA: Bullish | Apr 1, 2020 | 6 years ago |
| SMA: Bearish | Mar 1, 2020 | 6 years ago |
| MACD: Sell Signal | Mar 1, 2020 | 6 years ago |
| MACD: Buy Signal | Feb 1, 2020 | 6 years ago |
| SMA: Bearish | Jan 1, 2020 | 6 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| SMA: Bullish | Oct 1, 2019 | 7 years ago |
| SMA: Bearish | Jan 1, 2019 | 7 years ago |
| SMA: Bullish | Nov 1, 2018 | 8 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| MACD: Sell Signal | Jul 1, 2018 | 8 years ago |
| SMA: Bearish | Jun 1, 2018 | 8 years ago |
| RSI: Overbought | Sep 1, 2017 | 9 years ago |
| MACD: Buy Signal | May 1, 2017 | 9 years ago |
| SMA: Bullish | Mar 1, 2017 | 9 years ago |
| SMA: Bullish | Feb 1, 2017 | 9 years ago |
| SMA: Bearish | Jan 1, 2017 | 9 years ago |
| SMA: Bearish | Jan 1, 2017 | 9 years ago |
| SMA: Bullish | Nov 1, 2016 | 10 years ago |
| SMA: Bearish | Oct 1, 2016 | 10 years ago |
| SMA: Bearish | Oct 1, 2016 | 10 years ago |
| SMA: Bullish | Apr 1, 2016 | 10 years ago |
| SMA: Bullish | Apr 1, 2016 | 10 years ago |
| SMA: Bearish | Jan 1, 2016 | 10 years ago |
| SMA: Bullish | Oct 1, 2015 | 11 years ago |
| SMA: Bearish | Sep 1, 2015 | 11 years ago |
| SMA: Bearish | Aug 1, 2015 | 11 years ago |
| RSI: Overbought | Jul 1, 2015 | 11 years ago |
| SMA: Bullish | Apr 1, 2015 | 11 years ago |
| SMA: Bearish | Mar 1, 2015 | 11 years ago |
| RSI: Overbought | Sep 1, 2014 | 12 years ago |
Key statistics
- Market cap
- 519.48B
- Enterprise value
- 578.22B
- Trailing P/E
- 83.04
- Forward P/E
- 18.15
- PEG ratio
- 0.59
- Price / sales
- 8.07
- Price / book
- 0.00
- EPS (TTM)
- 3.54
- Beta
- 0.23
- Dividend yield
- 2.38%
- Payout ratio
- 190.40%
- Profit margin
- 9.80%
- Revenue (TTM)
- 64.39B
- Revenue growth
- 10.20%
- Free cash flow
- 16.87B
- Total cash
- 6.57B
- Total debt
- 70.88B
- Return on equity
- 0.00%
- Shares outstanding
- 1.77B
- Short % of float
- 0.98%
- 50-day average
- 268.63
- 200-day average
- 236.73
Analyst view
Consensus: buy
- Target (low)
- 200.00
- Target (mean)
- 283.19
- Target (high)
- 325.00
- Strong buy7
- Buy16
- Hold5
- Sell0
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 3.89.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 3.91 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 3.73 | 3.82 | +0.09 | +2.41% |
| Jul 31, 2026 | Jun 30, 2026 | 3.61 | 3.65 | +0.04 | +1.11% |
| Apr 29, 2026 | Mar 31, 2026 | 2.59 | 2.65 | +0.06 | +2.32% |
| Feb 4, 2026 | Dec 31, 2025 | 2.65 | 2.71 | +0.06 | +2.26% |
| Oct 31, 2025 | Sep 30, 2025 | 1.77 | 1.86 | +0.09 | +5.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Oct 21, 2026 | Barclays | main | Overweight | Overweight |
| Oct 13, 2026 | RBC Capital | reit | Outperform | Outperform |
| Oct 9, 2026 | UBS | main | Neutral | Neutral |
| Oct 9, 2026 | Guggenheim | reit | Buy | Buy |
| Oct 8, 2026 | JP Morgan | main | Overweight | Overweight |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- abbvie.com
News
- AbbVie: 3 Key Takeaways for Long-Term Investors
- Is AbbVie a Buy After Its Latest Earnings Report?
- Dividend Champion, Contender, And Challenger Highlights: Week November 1
- AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript
- What AbbVie (ABBV) Said on Its Q3 Earnings Call
- AbbVie Raises 2026 Outlook, Boosts Dividend
- AbbVie: Why I See More Upside After Q3
- ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
- Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings
Your note
Sign in to keep a note on ABBV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONOGHOE NICHOLAS | Officer | Sale | Aug 13, 2026 | 74,430 |
| FREYMAN THOMAS C | Director | Stock Award(Grant) | May 7, 2026 | 135,751 |
| GONZALEZ RICHARD A | Director | Stock Gift | Mar 30, 2025 | 386,479 |
| MICHAEL ROBERT A. | Chief Executive Officer | Stock Award(Grant) | Feb 17, 2026 | 215,260 |
| RAPP EDWARD J | Director | Stock Award(Grant) | May 7, 2026 | 45,964 |
| REENTS SCOTT T. | Chief Financial Officer | Stock Award(Grant) | Feb 17, 2026 | 60,415 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.46% | 149,488,412 | 43.95B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 115,396,098 | 33.92B | Jun 29, 2026 |
| State Street Corporation | 4.67% | 82,596,748 | 24.28B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.74% | 48,477,996 | 14.25B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.71% | 47,862,796 | 14.07B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.66% | 46,998,433 | 13.82B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 56,090,167 | 16.49B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 45,784,614 | 13.46B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,546,125 | 6.92B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 22,934,567 | 6.74B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,857,356 | 6.43B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.95% | 16,815,764 | 4.94B | Jun 29, 2026 |